Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 09, 2026 01:00 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse: Le rilzabrutinib de Sanofi a été désigné comme thérapie innovante aux États-Unis et comme médicament orphelin au Japon pour le traitement de l’anémie hémolytique auto-immune à anticorps chauds

Le rilzabrutinib de Sanofi a été désigné comme thérapie innovante aux États-Unis et comme médicament orphelin au Japon pour le traitement de l’anémie hémolytique auto-immune à anticorps chauds Le...
February 09, 2026 01:00 ET | Source: Sanofi Winthrop Industrie

Press Release: Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia

The US and Japan granted breakthrough therapy/orphan status to rilzabrutinib for wAIHA, a rare blood disorder marked by the destruction of red blood cells
July 29, 2025 13:51 ET | Source: Spherix Global Insights

Hematologist Dissatisfaction with Current Warm Autoimmune Hemolytic Anemia (w-AIHA) Treatment Spurs Interest in Late-Stage Pipeline, According to Spherix Global Insights

EXTON, PA, July 29, 2025 (GLOBE NEWSWIRE) -- According to new findings from Spherix Global Insights’ syndicated Market Dynamix™ service, hematologists managing patients with warm autoimmune...
May 13, 2025 15:01 ET | Source: Spherix Global Insights

Sanofi Garners Highest Physician Interest in Asthma Pipeline, Despite GSK’s Later-Stage Asset, According to Spherix Global Insights

EXTON, PA, May 13, 2025 (GLOBE NEWSWIRE) -- Although no new biologics for asthma have been approved since the 2021 launch of Tezspire (Amgen/AstraZeneca), recent insights from Spherix Global...